Evidence map›Paper›PMID 36438806›Full record

ArticleFrontiers in pharmacology2022

Corrigendum: Neurological adverse events associated with esketamine: A disproportionality analysis for signal detection leveraging the FDA adverse event reporting system.

Haoning Guo, Bin Wang, Shuying Yuan, Silin Wu, Jing Liu, Miaoquan He, Jisheng Wang

Open access · goldAbstract readPublished Erratum
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Clinical applications of esketamine: Current status and future perspectives.The Journal of international medical research · 2026
    Review
  3. Observational
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Haoning GuoDivision of Psychopharmacology, Department of Pharmacy, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, China.
Bin WangClinical Experimental Center, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-Sen University, Jiangmen, China.
Shuying YuanDivision of Psychopharmacology, Department of Pharmacy, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, China.
Silin WuDivision of Psychopharmacology, Department of Pharmacy, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, China.
Jing LiuDepartment of Pathology, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, China.
Miaoquan HeDivision of Psychopharmacology, Department of Pharmacy, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, China.
Jisheng WangDivision of Psychopharmacology, Department of Pharmacy, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, China.
Mianyang Third People's Hospital · CNJiangmen Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fphar.2022.849758.].

Indexed as

disproportionality analysisesketamineFAERSneurological adverse eventspharmacovigilancesignal

Identifiers

PMID36438806
PMCPMC9683689
OpenAlexW4308624733

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.